Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGNNYSE / NASDAQHealthcareLarge cap

$920.69-$2.65 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$65.9B
P/E
14.6x
EV / EBITDA
11.3x
Revenue
$14.3B
Net margin
31.4%
ROCE
10.2%

+24.9% over the last year

Regeneron Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+14.0%
3M
+11.4%
6M
+41.7%
1Y
+24.9%
5Y
+41.1%

52-week range

Day change -$2.65 (-0.3%) from $923 to $921 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in REGN, bought on each weekday since 2021.

News & filings

What Regeneron Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

Read moreShow less

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Sector
Healthcare
Shares outstanding
104.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$65.9B
P/E
14.6x
P/B
2.1x
EV / EBITDA
11.3x
EV / Sales
4.6x
P/S
4.6x
52-week high
$973.36
52-week low
$600.66

Profitability

Operating margin
25.8%
Net margin
31.4%
EBITDA margin
40.6%
ROE
14.4%
ROCE
10.2%
ROA
11.1%
Asset turnover
0.35

Growth

Revenue
$14.3B
Revenue growth, 1Y
1.0%
Revenue CAGR, 3Y
5.6%
Net profit growth, 1Y
2.1%
Free cash flow
$3.8B

Solvency

Current ratio
4.13
Debt / Equity
0.09
Debt / Assets
0.07
CFO / Net profit
1.11
Cash / Market cap
4.7%

Where the revenue went

Of every $100 of FY2025 revenue, $31 was left as net income.

Regeneron Pharmaceuticals, Inc. income statement flow, FY2025
Regeneron Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.1B
RevenueGross profit$12.2B
Gross profitOperating expenses$8.5B
Gross profitOperating income$3.7B
Operating incomePretax income$3.7B
Interest and other incomePretax income$1.5B
Pretax incomeTax and other$725.8M
Pretax incomeNet income$4.5B

Revenue and net profit

Revenue grew 1.0% in FY2025; net profit is the dashed line.

Regeneron Pharmaceuticals, Inc. revenue and net profit by fiscal year
Regeneron Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$12.2B$4.3B
FY2023$13.1B$4.0B
FY2024$14.2B$4.4B
FY2025$14.3B$4.5B

Cash flows

FY2025: $5.0B from operations, $3.8B free after investment (dashed).

Regeneron Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Regeneron Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$5.0B$3.4B
FY2023$4.6B$3.7B
FY2024$4.4B$3.5B
FY2025$5.0B$3.8B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$14.3B+1.0%1Y
EBITDA
$5.8B+9.4%1Y
Net profit
$4.5B+2.1%1Y
Cash from operations
$5.0B+12.6%1Y
Free cash flow
$3.8B+6.4%1Y
Revenue CAGR, 3Y
5.6%
Net profit CAGR, 3Y
1.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$14.3B$5.8B$4.5B$3.8B14.4%+1.0%+2.1%

Monthly returns

Month-by-month returns of REGN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$40.6B
Liabilities$9.3B
Equity$31.3B
Paid-in capital$14.0B
Retained earnings$35.8B
Treasury stock$18.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; REGN highlighted.

P/E against peers

REGN trades at 14.6x earnings against a peer median of 27.7x (a 47% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Regeneron Pharmaceuticals, Inc.REGNthis companyP/E ↓ discount$65.9B14.6x2.1x14.4%11.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
HCA Healthcare, Inc.HCA$80.3B11.8x-13.3x-112.6%8.2x
The Cigna GroupCI$74.2B12.5x1.8x14.3%10.2x
Boston Scientific CorporationBSX$72.6B25.1x3.0x12.0%16.1x
Cencora, Inc.COR$52.6B33.8x34.9x103.1%14.9x
Edwards Lifesciences CorporationEW$50.4B46.9x4.9x10.4%33.2x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Peer median—27.7x2.5x12.4%16.1x

Year-to-date ROI

REGN since 1 January, against earlier years.

Historical volatility

REGN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Regeneron Pharmaceuticals, Inc. operating margin by fiscal year
Regeneron Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY202238.9%
FY202330.9%
FY202428.1%
FY202525.8%
LineFY2025
Cost of revenueCost Of Revenue$2.1B
Gross profitGross Profit$12.2B
Operating expensesOperating Expense$8.5B
Research and developmentResearch And Development$5.9B
Selling, general and administrativeSelling General And Administration$2.7B
Other operating expensesOther Operating Expenses-$10.0M
Total expensesTotal Expenses$10.6B
Pretax incomePretax Income$5.2B

Learn while you research

Academy chapters picked for Regeneron Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →